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Skeletal remodeling requires recruitment of osteoblast precursors, in the form of MSCs, to the bone surface.
In this issue of Cell Stem Cell, Wu et al. (2010) demonstrate that this event is mediated by osteoclastic mobi-
lization of active transforming growth factor b1, which is inhibited by a common antiosteoporosis drug.Osteoporosis is endemic in developed
countries; approximately half of 65-year-
oldwhite or Asianwomen ultimately expe-
rience a spontaneous fracture. Regard-
less of cause, osteoporosis results from
an imbalance of osteoclasts and osteo-
blasts, wherein the net activities of the
former supersede the latter. Thus, osteo-
porosis therapy involves either suppres-
sion of bone resorption or stimulation of
formation. The discovery that intermittent
administration of parathyroid hormone
(PTH) stimulates bone formation yielded
the first and only bone anabolic drug
(Neer et al., 2001), but the most common
approach to preventing and treating oste-
oporosis is osteoclast inhibition.
Osteoclasts and osteoblasts have an
interdependent relationship; the recruit-
ment of each depends upon the other.
Osteoclastsdifferentiate frommacrophage
precursors under the aegis of RANK ligand
and M-CSF, produced by osteoblast
lineage cells.On the other sideof the equa-
tion, it is the bone-resorbing activity of
osteoclasts that attracts osteoblasts to
thebonesurface, aprocess knownasskel-
etal remodeling. This ever-occurring event
consists of focal removal and subsequent
replacement of bone. Thus, bone remodel-
ing is characterized by tethering of osteo-
clast and osteoblast recruitment and
function. If remodeling is imbalanced and
the magnitude of resorption surpasses
formation, osteoporosis ensues.
Patients lose bone by two general
mechanisms that are dictated by remod-
eling kinetics. Estrogen deficiency, which
represents the most common cause of
osteoporosis, is a high turnover state in
which both formation and resorption are
accelerated, but the relative activity of
the osteoclast is greater than that of the
osteoblast. Consequently, suppression
of the osteoclast by hormone replace-
ment had been the standard of care fordecades. With the realization that estro-
gens increase risk of breast cancer and
cardiovascular complications in older
women, bisphosphonates, which directly
target osteoclasts, have become the
most common treatment for postmeno-
pausal osteoporosis. Given the absolute
increase in osteoclast activity in es-
trogen-deficient osteoporosis, the effec-
tiveness of bisphosphonates is not
surprising. These drugs are nonhydrolyz-
able pyrophosphate analogs that bind
bone mineral with extremely high affinity
and reside within the skeleton until
mobilized by osteoclasts. Alendronate,
the most commonly administered bi-
sphosphonate, maintains bone mass
and reduces fracture risk of postmeno-
pausal, osteoporotic women for as long
as a decade with minimal complications
in the great majority of patients (Bone
et al., 2004). The capacity of bisphospho-
nates to enhance bone mass reflects the
fact that it incapacitates osteoclasts and
thus dampens remodeling.
The most common secondary form of
osteoporosis is that induced by glucocor-
ticoids, but its skeletal dynamics are
distinctly different than those resulting
from estrogen deprivation. Whereas bone
remodeling is accelerated with meno-
pause, it is suppressed by prolonged
administration of glucocorticoids. Thus,
glucocorticoid-induced osteoporosis
represents a low remodeling form of the
disease in which both formation and
resorption are suppressed but the former
is more so than the latter. Stimulation of
bone formation by intermittent PTH
administration represents the most effec-
tive current approach to this condition,
but most patients are treated with
bisphosphonates, which further suppress
remodeling.
Because osteogenesis is coupled to
resorption in the remodeling process,Cell Stem Cell 7,alendronate’s antiosteoclastic properties
blunt the bone-forming capacity of simul-
taneously administered PTH (Black et al.,
2003). Because the principal role of
remodeling is probably to replace effete
bone with new, its prolonged suppression
probably compromises the skeleton’s
biomechanical properties and evidence
indicates such is the case with alendro-
nate (Allen and Burr, 2007). Thus, under-
standing the specific mechanism by
which bisphosphonates suppress osteo-
clast activity is central to developing anti-
resorptive strategies that spare bone
formation.
Although remodeling has been known
for decades to be essential for skeletal
integrity, the means by which osteoclasts
recruit osteoblasts to the site of resorption
is among the most important yet enig-
matic issues regarding skeletal biology
and treating osteoporosis. Last year
Tang et al. (2009) demonstrated that
active TGF-b1 is a likely molecule
attracting osteoblasts to sites of prior
osteoclast activity. In this scenario, the
activated growth factor, mobilized from
bone matrix by osteoclasts, establishes
a gradient that attracts Sca1+CD29+
CD45CD11b mesenchymal stem cells
to sites of bone resorption where they
putatively undergo osteoblast differentia-
tion. In the current issue of Cell Stem
Cell, the same group extends these
observations to the practical issue of
treating osteoporosis with bisphospho-
nates (Wu et al., 2010).
To determine the mechanism by which
alendronate blunts bone formation,
Wu et al. (2010) first asked whether the
drug arrests PTH-stimulated osteoblast
differentiation. This model was not sup-
ported by their results, despite observing
reduced osteogenesis and a decreased
number of bone-forming cells, in vivo,
a circumstance reminiscent of absenceNovember 5, 2010 ª2010 Elsevier Inc. 553
Figure 1. Alendronate Suppresses PTH-Stimulated Bone
Formation by Inhibiting Osteoclast-Mediated Mobilization of
Activated TGF-b1
PTH stimulates osteoblasts (OB) to produce RANKL and M-CSF.
These cytokines induce marrow macrophage lineage cells (MV) to
differentiate intomature osteoclasts (OC) that initiate remodeling by re-
sorbing a focal packet of bone. Latent TGF-b1 is mobilized from re-
sorbed bone and activated by the osteoclast. A gradient of activated
TGF-b1 (aTGF-b1) recruits osteoblast precursors in the form of
Sca1+CD29+CD45CD11bmesenchymal stem cells (MSC) to the re-
modeling site where they differentiate into osteoblasts that replace the
previously resorbed bone. Alendronate directly inhibits osteoclasts,
thereby arresting TGF-b1 mobilization and thus bone formation.
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In Translationof active TGF-b1, which recruits
osteoblast precursors to the
bone surface (Tang et al., 2009).
In fact, the authors found that
although the abundance of total
TGF-b1 in bone marrow is
unaffected by treatment with
PTH and alendronate, alone or
in combination, the hormone in-
creases the active state of the
growth factor while the bi-
sphosphonate reduces it. This
outcome is mirrored by the
number of cells expressing
Smad2/3, which this group es-
tablished mediates migration of
osteogenic precursors to remod-
eling sites (Tang et al., 2009). The
authors also find that absence
of TGF-b1, in mice, prevents
PTH-stimulated bone formation.
Alendronate does not alter differ-
entiation of TGF-b1/ osteo-
blasts, in vitro, but reduces their
PTH-stimulated abundance,
in vivo. Thus, the bisphospho-nate, whose sole established direct target
in vivo is osteoclasts, probably inhibits
bone formation by arresting active TGF-
b1 mobilization from bone matrix, thereby
preventing recruitment of mesenchymal
stem cells to remodeling sites. Expanding
upon their previous observations, the
authors propose that the target osteo-
blast precursors cells are
Sca1+CD29+CD45CD11b. To deter-
mine whether such is the case, they
isolated and expanded multipotential
mesenchymal cells with this phenotype.
Confirming their osteogenic capacity,
in vivo, these cells form bonewhen placed
under the renal capsule. Finally, the
authors demonstrate that TGF-b1/
mice fail to normally recruit Sca1+
CD29+CD45CD11b cells to the bone
surface in response to PTH. These studies
indicate that alendronate suppresses
PTH-stimulated bone formation by inhibit-
ing osteoclast-mediated mobilization of
active TGF-b1, thereby reducing migra-554 Cell Stem Cell 7, November 5, 2010 ª20tion of osteoblast precursors to sites of re-
modeling (Figure 1).
Currently, osteoporosis patients are
limited to 2 year cycles of PTH treatment.
Thus, a logical strategy to prevent loss of
accumulated bone is to utilize an antire-
sorptive agent between episodes of PTH
administration (Black et al., 2005). Wu
et al. (2010) predict that unlike simulta-
neous administration of the two drugs,
this sequential strategy will not suppress
bone formation because osteoclast-
mediated mobilization of TGF-b1 will be
intact during PTH-only cycles (Tang
et al., 2009). This hypothesis is chal-
lenged, however, by the decade-long
persistence of bisphosphonates in the
skeleton after cessation of their adminis-
tration (Drake et al., 2008). The elegant
experiments of the Cao laboratory under-
score the necessity of developing short-
acting antiresorptive agents that will
permit recovery of osteoclast-mediated
mobilization of the growth factor during10 Elsevier Inc.the period of anabolic therapy
(Wu et al., 2010, this issue;
Tang et al., 2009). The translation
of observations in mice into
current antiosteoporosis drugs
holds promise that the present
studies will yield the same (Eis-
man et al., 2010; McClung
et al., 2006).REFERENCES
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